Finoriq research workspace
Nuvation Bio Inc. (NUVB) Company Overview
Review a simplified SEC filing overview, TradingView market widgets, and reported line items for Nuvation Bio Inc. (NUVB).
Company Snapshot
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Company
- Nuvation Bio Inc. (NUVB)
- Ticker
- NUVB
- Market Cap
- $2.2B
- Latest Price
- $6.29
- Industry
- Biotech & Pharma
Nuvation Bio Inc. (NUVB) Current Valuation Metrics
Static valuation preview for Nuvation Bio Inc. (NUVB). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 32.4x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -10.1% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -8.5% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 6.66x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.